|

Lupus Clinical Trials in Texas

38 recruiting studies across 7 cities

Browse by City

Arlington
26 trials
Dallas
26 trials
Fort Worth
26 trials
Houston
23 trials
Austin
4 trials
El Paso
4 trials
San Antonio
4 trials

All Trials in Texas

Phase
Trial Phase Dist.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus ErythematosusPhase 2<1 mi
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Phase 2<1 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 4<1 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPhase 2/3<1 mi
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusPhase 3<1 mi
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE ParticipantsPhase 1/2<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 2<1 mi
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)Phase 1<1 mi
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus NephritisPhase 2<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPhase 3<1 mi
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentPhase 3<1 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants—<1 mi
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsPhase 2<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 3<1 mi
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPhase 2<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/2<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 1<1 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 2<1 mi
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Phase 2<1 mi
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersPhase 1/2<1 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyPhase 2<1 mi
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors—<1 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/2<1 mi
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus NephritisPhase 1<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisPhase 4<1 mi
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsPhase 1<1 mi
Cutaneous Lupus Registry—<1 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—<1 mi
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus—<1 mi
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy TrialPhase 42 mi
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Phase 37 mi
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusPhase 312 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPhase 118 mi
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Phase 118 mi
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsPhase 124 mi
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePhase 324 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.